AV7909 + BioThrax
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anthrax
Conditions
Anthrax
Trial Timeline
Mar 11, 2019 → Aug 6, 2020
NCT ID
NCT03877926About AV7909 + BioThrax
AV7909 + BioThrax is a phase 3 stage product being developed by Emergent BioSolutions for Anthrax. The current trial status is completed. This product is registered under clinical trial identifier NCT03877926. Target conditions include Anthrax.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03877926 | Phase 3 | Completed |
| NCT01770743 | Phase 2 | Completed |
Competing Products
15 competing products in Anthrax